United States: Federal Circuit Defines Supplier Exemption To The On-Sale Bar

On July 11, 2016, the Federal Circuit in The Medicines Co. v. Hospira, Inc., No. 14-1469 (Fed. Cir. July 11, 2016) (O'Malley, J.) (en banc) narrowed the reach of the on-sale bar under 35 U.S.C. § 102(b) to exclude contract manufacturing activities, provided certain criteria are met. The Court held that even though some commercial benefit may be obtained by each party to a contract manufacture agreement, where the inventor retains control of the product and is the limited recipient of the manufactured product, the on-sale bar is not triggered. This was true even where the volume of manufactured product may be considered a "stockpile" for subsequent distribution. The Court remanded the case for further consideration of a related issue of whether a distribution agreement constituted an "offer for sale."

In addressing this contract manufacturing issue, the Federal Circuit provided further guidance as to how to apply the first prong of the Supreme Court's Pfaff decision. Under Pfaff, an on-sale bar occurs when, before the critical date, the claimed invention was (1) the subject of a commercial offer for sale; and (2) was ready for patenting. The Court's unanimous holding looked to Section 2-106 of the Uniform Commercial Code to guide application of the "commercial offer for sale" prong of Pfaff. Specifically, the Federal Circuit held that in order for an alleged sale to be a commercial sale triggering 102(b), the sale must "bear the general hallmarks of a commercial sale pursuant to Section 2-106 of the Uniform Commercial Code." Slip op. at 3.

Applying this rule to the issue of whether the contract manufacturer "sold" the product to MedCo, the court concluded that no sale, for purposes of assessing novelty, had occurred, identifying three reasons for its judgment in this case:

  1. Only manufacturing services were sold to the inventor—the invention was not;
  2. The inventor maintained control of the invention, as shown by the retention of title to the embodiments and the absence of any authorization to the contract manufacturer to sell the product to others; and
  3. "Stockpiling," standing alone, does not trigger the on-sale bar.

Slip op. at 19. This holding is significant because companies which outsource their manufacturing can now better understand how to avoid having commercial manufacturing activities considered to constitute an on-sale bar—i.e., by carefully maintaining control of the invention and limiting distribution from the commercial manufacturer to the inventor and not to the public generally. Although the relevant novelty statute (35 U.S.C. § 102) has changed following implementation of the America Invents Act ("AIA"), these considerations are still relevant with respect to the post-AIA novelty statute, which changed the date on which certain activities constitute an on-sale bar, but not the types of activities that constitute an on-sale bar. (We note that a similar on-sale bar issue, but under the new, post-AIA statute, is currently pending at the Federal Circuit in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., Nos. 16-1284, 16-1787 (Fed. Cir.).)

MedCo was seeking FDA approval of a generic form of a branded product. However, the original process MedCo used to prepare the product also produced a by-product, which made the product less shelf-stable. MedCo developed a new process, and engaged BenVenue, a contract manufacturer, to perform this chemistry on the commercial scale and provide MedCo with sufficient material to obtain FDA approval.

In terms of the contract manufacturing activity, MedCo paid BenVenue to make and deliver what was, in fact, a commercial quantity of the drug product in question. MedCo quarantined the product for an extended period of time to verify that it was shelf-stable. Once it was determined that the product was shelf-stable, MedCo sought patent protection. While the drug product itself was known, the new process produced a product with sufficiently low levels of the by-product. MedCo therefore sought and obtained "product-by-process" claims.

One of the key facts in this case is that BenVenue's "sale" of the drug product to MedCo occurred more than a year before MedCo's patent applications were filed.

MedCo's abbreviated new drug application ("ANDA") had to be approved by the U.S. Food and Drug Administration ("FDA") before MedCo's first commercial sale could occur, and the FDA could not approve the ANDA without verifying that MedCo's product met the necessary specifications. MedCo filed its patent applications before the ANDA was approved, and before MedCo's first commercial sale.

Since BenVenue's sale to MedCo occurred more than one year before MedCo filed for patent protection, Hospira argued that the sale by BenVenue invalidated MedCo's patent claims.

Accordingly, one of the key issues before the court was whether the date on which BenVenue sold the product to MedCo triggered an on-sale bar, in which case MedCo's patent claims would be invalid, or whether the date on which MedCo first sold its product is the relevant date, in which case MedCo's patent claims would not be invalidated by BenVenue's sale to MedCo.

Hospira also asserted that when MedCo stockpiled its product, this constituted a sale. Hospira contended that where a transaction provides a commercial benefit to the inventor, it is enough to trigger the on-sale bar (even though the stockpiled product was not yet sold), under a theory that MedCo received a commercial benefit from BenVenue by being able to stockpile its product for future sale.

In the earlier panel decision, the court had agreed with Hospira that contract manufacturing and stockpiling product for a later sale each constituted a sale because MedCo received a commercial benefit from the transactions with its contract manufacturer. The panel reasoned that, because MedCo paid its contract manufacturer for services that resulted in the patented product, the transactions were commercial sales. Medicines Co. v. Hospira, Inc., 791 F.3d 1370-71 (Fed. Cir. 2015).

MedCo petitioned for a panel rehearing or a rehearing en banc, which was granted on November 13, 2015. The panel's decision was vacated, the appeal was reinstated, and new briefing was ordered on a) whether the circumstances constituted a commercial sale, b) whether there was a sale, despite the absence of a transfer of title, c) whether the sale was commercial, or an experimental use, and d) whether the court should overrule or revise the principle in Special Devices, Inc. v. OEA, Inc., 270 F.3d 1353 (Fed. Cir. 2001), that there is no "supplier exception" to the on-sale bar of 35 U.S.C. § 102(b).

The full court has now appeared to revise the principle in Special Devices, by outlining relevant considerations under which there can be a "supplier exception" to the on-sale bar.

The full court evaluated the term "sale" as being a "commercial sale," pursuant to various UCC provisions. In a typical sale under the UCC, title to a product typically transfers from the manufacturer to the purchaser at some point after the purchase price is paid, and the product is shipped. In the instant case, title to the product always remained with MedCo, so this was one factor the court considered in determining that BenVenue's activities did not constitute a "commercial sale" for purposes of assessing novelty.

Further, in a typical "commercial sale," there is typically a reasonable correlation between the price paid for a product and the market value of the product. In this case, the product is a high-priced biological product. The price MedCo paid BenVenue related more to the cost of performing toll synthesis than the value of the product.

Looking at these factors, the court determined that BenVenue's activities did not constitute a commercial sale for purposes of establishing a lack of novelty.

One likely take-home message to companies outsourcing their product manufacturing is that, until their patent application is on file, they should ensure that title to the product being manufactured does not transfer, that the manufacturer is not permitted to sell the product to others, and that all transactions with the product manufacturer are held in confidence.

It is still possible that entering into a Distribution Agreement before a patent application is filed could be construed as an offer for sale, and this will be determined on remand. Further, Hospira could petition the Supreme Court to overturn the Federal Circuit's approach to a "supplier exception" to the on-sale bar. Since many small companies, including those in the pharma and biotech industries, outsource their manufacturing, and may do so before filing for patent protection, we expect that many amici will also weigh in with their views about the Federal Circuit's approach if this issue is considered by the Supreme Court.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions